Stent a rilascio di farmaco: Dai risultati degli studi clinici ai modelli di impatto economico-sanitario nella realtà Italiana

Translated title of the contribution: Drug-releasing stent: From the result of the clinical studies to the models of economic-health impact in the Italian reality

Giuseppe Sangiorgi, Peppa Rodamni, Flavio Airoldi, Antonio Colombo

Research output: Contribution to journalArticle

Abstract

Several studies with drug-eluting stents (DES) have demonstrated dramatic reductions in restenosis rates compared with bare metal stents (BMS). Although the clinical benefits of DES are increasingly evident, important concerns about their costs have been raised. Most data regarding the impact of restenosis on long-term costs after percutaneous coronary intervention (PCI) are derived from clinical trials. These studies demonstrate that there is no single cost or economic burden of restenosis; these values vary substantially according to the specific patient population under investigation and to the healthcare system reality where they are applied. In the present study we propose an economic interactive decision model which was applied to the Italian healthcare system, considering the different reimbursement rates of the Italian regions for DES and for both PCI and coronary artery bypass surgical interventions (CABG). The aim of this model was to simulate the impact of DES introduction after potential complete reimbursement by the national healthcare system, hypothesizing the usage of 1.4 stent per patient in case of single vessel disease and 2.4 stents in case of multivessel disease, and utilizing the TAXUS IV rate of revascularization for reintervention costs calculation and the ARTS-I study for CABG costs. For a low risk patients' population, the mean cost of a procedure with DES was 6% greater than utilizing BMS (€ 8125 for DES vs € 7651 for BMS). However, this percentage was reduced in case of diabetic patients (+4%), long lesions (+2%) and was favourable for small vessels (-3%). In addition, in case of multivessel disease with conversion from CABG to DES, the 12 months cost per patients was reduced of around 30% (€ 10170 for PCI vs € 14 584 for CABG). This model suggests that national helthcare system may save 2.1% of the total costs (€ 18.60 millions) if 60% of revascularization procedures converts to total DES utilization and 15% from CABG to PCI with DES.

Original languageItalian
Pages (from-to)145-156
Number of pages12
JournalItalian Heart Journal Supplement
Volume6
Issue number3
Publication statusPublished - Mar 2005

Fingerprint

Economic Models
Drug-Eluting Stents
Stents
Costs and Cost Analysis
Health
Pharmaceutical Preparations
Percutaneous Coronary Intervention
Metals
Delivery of Health Care
Economics
Clinical Studies
Coronary Artery Bypass
Population
Clinical Trials

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Stent a rilascio di farmaco : Dai risultati degli studi clinici ai modelli di impatto economico-sanitario nella realtà Italiana. / Sangiorgi, Giuseppe; Rodamni, Peppa; Airoldi, Flavio; Colombo, Antonio.

In: Italian Heart Journal Supplement, Vol. 6, No. 3, 03.2005, p. 145-156.

Research output: Contribution to journalArticle

@article{44c42cb80b73462b87c2b7207ccac482,
title = "Stent a rilascio di farmaco: Dai risultati degli studi clinici ai modelli di impatto economico-sanitario nella realt{\`a} Italiana",
abstract = "Several studies with drug-eluting stents (DES) have demonstrated dramatic reductions in restenosis rates compared with bare metal stents (BMS). Although the clinical benefits of DES are increasingly evident, important concerns about their costs have been raised. Most data regarding the impact of restenosis on long-term costs after percutaneous coronary intervention (PCI) are derived from clinical trials. These studies demonstrate that there is no single cost or economic burden of restenosis; these values vary substantially according to the specific patient population under investigation and to the healthcare system reality where they are applied. In the present study we propose an economic interactive decision model which was applied to the Italian healthcare system, considering the different reimbursement rates of the Italian regions for DES and for both PCI and coronary artery bypass surgical interventions (CABG). The aim of this model was to simulate the impact of DES introduction after potential complete reimbursement by the national healthcare system, hypothesizing the usage of 1.4 stent per patient in case of single vessel disease and 2.4 stents in case of multivessel disease, and utilizing the TAXUS IV rate of revascularization for reintervention costs calculation and the ARTS-I study for CABG costs. For a low risk patients' population, the mean cost of a procedure with DES was 6{\%} greater than utilizing BMS (€ 8125 for DES vs € 7651 for BMS). However, this percentage was reduced in case of diabetic patients (+4{\%}), long lesions (+2{\%}) and was favourable for small vessels (-3{\%}). In addition, in case of multivessel disease with conversion from CABG to DES, the 12 months cost per patients was reduced of around 30{\%} (€ 10170 for PCI vs € 14 584 for CABG). This model suggests that national helthcare system may save 2.1{\%} of the total costs (€ 18.60 millions) if 60{\%} of revascularization procedures converts to total DES utilization and 15{\%} from CABG to PCI with DES.",
keywords = "Coronary artery bypass graft, Stent",
author = "Giuseppe Sangiorgi and Peppa Rodamni and Flavio Airoldi and Antonio Colombo",
year = "2005",
month = "3",
language = "Italian",
volume = "6",
pages = "145--156",
journal = "Italian Heart Journal Supplement",
issn = "1129-4728",
publisher = "Centro Editoriale Pubblicitario Italiano",
number = "3",

}

TY - JOUR

T1 - Stent a rilascio di farmaco

T2 - Dai risultati degli studi clinici ai modelli di impatto economico-sanitario nella realtà Italiana

AU - Sangiorgi, Giuseppe

AU - Rodamni, Peppa

AU - Airoldi, Flavio

AU - Colombo, Antonio

PY - 2005/3

Y1 - 2005/3

N2 - Several studies with drug-eluting stents (DES) have demonstrated dramatic reductions in restenosis rates compared with bare metal stents (BMS). Although the clinical benefits of DES are increasingly evident, important concerns about their costs have been raised. Most data regarding the impact of restenosis on long-term costs after percutaneous coronary intervention (PCI) are derived from clinical trials. These studies demonstrate that there is no single cost or economic burden of restenosis; these values vary substantially according to the specific patient population under investigation and to the healthcare system reality where they are applied. In the present study we propose an economic interactive decision model which was applied to the Italian healthcare system, considering the different reimbursement rates of the Italian regions for DES and for both PCI and coronary artery bypass surgical interventions (CABG). The aim of this model was to simulate the impact of DES introduction after potential complete reimbursement by the national healthcare system, hypothesizing the usage of 1.4 stent per patient in case of single vessel disease and 2.4 stents in case of multivessel disease, and utilizing the TAXUS IV rate of revascularization for reintervention costs calculation and the ARTS-I study for CABG costs. For a low risk patients' population, the mean cost of a procedure with DES was 6% greater than utilizing BMS (€ 8125 for DES vs € 7651 for BMS). However, this percentage was reduced in case of diabetic patients (+4%), long lesions (+2%) and was favourable for small vessels (-3%). In addition, in case of multivessel disease with conversion from CABG to DES, the 12 months cost per patients was reduced of around 30% (€ 10170 for PCI vs € 14 584 for CABG). This model suggests that national helthcare system may save 2.1% of the total costs (€ 18.60 millions) if 60% of revascularization procedures converts to total DES utilization and 15% from CABG to PCI with DES.

AB - Several studies with drug-eluting stents (DES) have demonstrated dramatic reductions in restenosis rates compared with bare metal stents (BMS). Although the clinical benefits of DES are increasingly evident, important concerns about their costs have been raised. Most data regarding the impact of restenosis on long-term costs after percutaneous coronary intervention (PCI) are derived from clinical trials. These studies demonstrate that there is no single cost or economic burden of restenosis; these values vary substantially according to the specific patient population under investigation and to the healthcare system reality where they are applied. In the present study we propose an economic interactive decision model which was applied to the Italian healthcare system, considering the different reimbursement rates of the Italian regions for DES and for both PCI and coronary artery bypass surgical interventions (CABG). The aim of this model was to simulate the impact of DES introduction after potential complete reimbursement by the national healthcare system, hypothesizing the usage of 1.4 stent per patient in case of single vessel disease and 2.4 stents in case of multivessel disease, and utilizing the TAXUS IV rate of revascularization for reintervention costs calculation and the ARTS-I study for CABG costs. For a low risk patients' population, the mean cost of a procedure with DES was 6% greater than utilizing BMS (€ 8125 for DES vs € 7651 for BMS). However, this percentage was reduced in case of diabetic patients (+4%), long lesions (+2%) and was favourable for small vessels (-3%). In addition, in case of multivessel disease with conversion from CABG to DES, the 12 months cost per patients was reduced of around 30% (€ 10170 for PCI vs € 14 584 for CABG). This model suggests that national helthcare system may save 2.1% of the total costs (€ 18.60 millions) if 60% of revascularization procedures converts to total DES utilization and 15% from CABG to PCI with DES.

KW - Coronary artery bypass graft

KW - Stent

UR - http://www.scopus.com/inward/record.url?scp=28244471692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28244471692&partnerID=8YFLogxK

M3 - Articolo

C2 - 15875500

AN - SCOPUS:28244471692

VL - 6

SP - 145

EP - 156

JO - Italian Heart Journal Supplement

JF - Italian Heart Journal Supplement

SN - 1129-4728

IS - 3

ER -